

## CV

<b>NAME</b> (First, Middle, Last)	<b>LAURENTIA NICOLETA GALES (previously MINEA)</b>
<b>TITLE</b>	MD PhD
<b>WORK ADDRESS</b> (Name of Institution/ Street/City/Postal Code/Country)	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest <b>Head of Department Medical Oncology II</b> Fundeni Road no 252, 2nd District, 022328, Bucharest, Romania University of Medicine and Pharmacy "Carol Davila" Bucharest <b>Associate Professor</b>
<b>CURRENT POSITION</b>	<b>Head of Department Medical Oncology II</b> Senior Medical Oncologist <b>Associate Professor</b>
<b>PHONE</b>	+40 21 227 1487
<b>MOBILE</b>	+40 722 651 583
<b>FAX</b>	
<b>EMAIL</b>	laurentia.gales@yahoo.com

### I. EDUCATION

Year(s)	Name of University	Degree details	Medical License Number (if applicable)
2024	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest	Senior radiotherapist	
2015	University of Medicine and Pharmacy "Carol Davila" Bucharest	PhD	
2015	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest	Specialist in Radiotherapy	1152/mar 2015
2008	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest	Senior Medical Oncologist	398/15/12.2008 B06-1012/4
1997-2002	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest	Medical Oncologist	256/03.2002
1990-1995	"Ovidius" University of Medicine and Pharmacy Constanta	Medical Doctor	Medical Licensure – no N023109

### II. PROFESSIONAL EXPERIENCE

Year(s)	Position	Name of Institution
2016 - present	Associate Professor	University of Medicine and Pharmacy "Carol Davila" Bucharest

2009 – 2016	Lecturer	University of Medicine and Pharmacy “Carol Davila” Bucharest
2003-2009	Assistant professor	University of Medicine and Pharmacy “Carol Davila” Bucharest
2008-present	Senior Medical oncologist	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest
2003-2008	Medical oncologist	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest
2002-2003	Medical oncologist	St John Clinical Hospital Bucharest - Ambulatory
1997-2002	Rezident in Medical oncology	Institute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest

### Professional Societies:

ESMO (European Society of Medical Oncology) since 2000

ASCO (American Society of Clinical Oncology) since 2001

RSM (The Royal Society of Medicine)

SIOG (International Society of Geriatric Oncology), since 2018, National representative – 2018-2019, 2024

SNOMR (Societatea Națională de Oncologie Medicală din România)

SRR (Societatea Română de Radioterapie)

SRROM (Societatea Română de Radioterapie și Oncologie Medicală)

### Basic research:

#### PhD thesis

**Study, research and application in clinical oncology of boron-10 neutron capture therapy**

#### National projects

1. BNCT. Studiul, cercetarea și abordarea în clinica oncologică a radioterapiei cu neutroni captati de către Bor-10 – PC-D01-PT11-94 (2005)
2. TARD. Dezvoltarea și testarea unui sistem automat de analiză a riscului, diagnostic și decizie pentru asistarea actului medical – PC-D03-PT03-1244 (2005)
3. Proiect VIASAN 435 – “Testarea genetică la femeile cu risc de neoplasm mamar ereditar” – Proiect al fundației Dr V Babes cu Partener Institutul Oncologic A Trestioreanu București – responsabil de proiect
4. PNRR-III-C9-2022 – I5 - Crearea, Operaționalizarea și Dezvoltarea Centrului Național de Competență în domeniul cancerului – **responsabil WP2 (WP leader) CD2 UMFC**
5. DR LASER – Medical Applications of High Power Laser – team member

#### International projects

1. **EU4H** - EU4H-2021-PJ-02 – INTERACT-EUROPE - Innovative collaboration for Inter-specialty cancer training across Europe – Director de proiect din partea partener UMFC
2. **EU4H** - EU4H-2022-PJ-01 – SOLACE - Strengthening the screening of Lung Cancer in Europe – partener UMFC – membru în echipa de proiect
3. **EU4H** - EU4H-2022-PJ-06 – TRANSITION - Digital TRANSition and dIGiTal resilience in ONcology – Membru în echipa de proiect – partener UMFC
4. **EU4H** - EU4H-2022-PJ-14 – INTERACT-EUROPE 100 - Director de proiect din partea partener UMFC

## **Clinical research (clinical trials):**

### **Sub-Investigator:**

1. H3E-MC-JMEN Maintenance Therapy Studiu de faza 3, dublu-orb, controlat placebo, al pemetrexed de intretinere plus cea mai buna asistenta suportiva versus cea mai buna asistenta suportiva imediat dupa tratamentul de inducere pentru cancer pulmonar avansat fara celule mici
2. CECOG/ GIST 1.2.001 Studiu clinic deschis utilizand Glivec la pacienti cu tumori gastrointestinale neoperabile sau metastatice maligne cu c-kit exprimat
3. H3E-MC-JMDV Studiu clinic de faza ½ privind cresterea dozei de Alimta si Cyclophosphamida administrate la fiecare 21 de zile la pacientele cu cancer de san local avansat sau metastatic
4. 3066A1-303-WW Studiu de faza 3 randomizat, controlat placebo, dublu-orb al administrarii orale a CCI-779 in combinatie cu Letrozole versus Letrozole singur ca terapie hormonala de prima linie la femeile postmenopauza cu cancer de san local avansat sau metastatic
5. CECOG/CORE 1.2.001 Studiu de faza II, deschis, randomizat care evalueaza eficacitatea si siguranta folosirii tratamentului cu FOLFOX 6 + CETUXIMAB versus FOLFIRI + CETUXIMAB ca prima linie de tratament la pacientii cu cancer colorectal metastazat.
6. MO18024 Tratament de prima linie cu bevacizumab in combinatie cu chimioterapia in cancerul colorectal metastatic
7. A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer – H3E-MC-JMHO
8. EFC10547 – VANILLA - A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
9. H3E-MC-JMHR A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
10. CECOG/CORE 1.2.002 A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + Weekly Cetuximab versus FOLFOX4 + biweekly Cetuximab as first line therapy in patients with k-ras wild-type metastatic colorectal cancer
11. KF5503/15 A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor-related pain
12. EMR 63325 A multi-center phase III randomized, double blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.
13. CECOG/BC.1.3.005: “A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer”
14. BO21990 - A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma - AVAGLIO
15. A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab, in patients with HER2-positive metastatic breast

cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting – PHEREX

16. CELLTRION CT-P6 - 3.1 / A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer
17. A randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition of Cp-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer – A4021017
18. EFC 11784 - Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m<sup>2</sup> and at 20 mg/m<sup>2</sup> in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
19. EFC11785 / randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m<sup>2</sup> and at 25 mg/ m<sup>2</sup> Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration resistant Prostate cancer Previously Treated With a Docetaxel-Containing Regimen.
20. Efficacy and Safety of long-Term (6 Months) Innohep® Treatment versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT
21. AMG 386 Protocol No. 20090508 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
22. An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy. – PCR3001
23. A Phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
24. A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7,5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit.
25. A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer. – AMG20100007
26. BROCADE - A Randomised, Phase 2 Study of the Efficacy and Tolerability of Veliparib in combination with Temozolomide or Veliparib in combination with Carboplatin and Paclitaxel versus Placebo plus Carboplatin and Paclitaxel in Subjects with BRCA 1 or BRCA 2 Mutation and Metastatic Breast Cancer.
27. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy
28. A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
29. MK-0517-031 AM4 - A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant

- Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
30. A double-blind placebo-controlled, randomized, multicentric, Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2 –positive metastatic gastroesophageal junction and gastric cancer JACOB, BO25114
  31. A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
  32. NBTXR-301 Multicenter randomized, open-label phase II/III study, to compare efficacy of NBTXR3 implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma (extremity and trunk wall)
  33. eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy - I3Y-MC-JPCW
  34. LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET FusionPositive Non-Small Cell Lung Cancer - J2G-MC-JZJC
  35. CheckMate 9LA - A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
  36. CheckMate 907 - An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen
  37. CheckMate 743 - A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
  38. CheckMate 227 - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
  39. CheckMate 915 - A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
  40. CARMEN-LC03, EFC15858 - Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors
  41. ALTA-3 - A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
  42. ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
  43. DS8201-A-U305 (DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001; AGO-B-050) A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of

Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (TDM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

44. A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non- Small Cell Lung Cancer – CA209-77T
45. A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy – CA209-67T
46. A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer – CA209-7DX
47. ANAM-17-21 A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
48. Un studiu de faza III, deschis, randomizat pentru a evalua eficacitatea si siguranta terapiei adjuvante cu alectinib versus chimioterapia adjuvanta cu compusi de platina la pacienti cu cancer pulmonar fara celule mici cu status pozitiv pentru kinaza din limfomul anaplazic, in stadiul IB complet rezecat (tumori  $\geq 4$  cm) pana la stadiul IIIA. (BO40336\_ALINA)
49. A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C. (CodeBreak 100)
50. A Phase 3 Study of Front-Line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/Metastatic NSCLC (CodeBreak 202)
51. Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated *MET*-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) (LUMINOSITY M14-239)
52. Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)
53. A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma- R3767-ONC-2011
54. A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma - R3767-ONC-2055

**Principal investigator:**

55. BESTFACT – Bonefos Treatment for Advanced Cancer – Studiu non-interventional, observational, post-autorizare despre utilizarea Bonefos (disodium clodronate) administrat oral in tratamentul tumorilor maligne cu afectare osoasa, in conditiile practicii medicale curente.
56. Studiu clinic multicentric, deschis, de faza II, evaluand eficacitatea tratamentului cu Tarceva prescris ca monoterapie, in linia 1, la pacientii cu tip de cancer NSCLC ce prezinta mutatii la nivelul receptorului EGFR – ML22606
57. CRAD001YIC04 An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who

- have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane
58. MK3475-059 A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
  59. GO29294 A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy [imvigor211]
  60. CORAIL Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer
  61. A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
  62. ARCHES – A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
  63. GLOW - A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
  64. NERO – Impact of the Adherence to Antiemetic Guidelines in Cancer Patients Undergoing Repeated Cycles of Either MEC or HEC Regimens in Eastern Europe
  65. AB12008 - A prospective, multicenter, open label, centrally allocated, active-controlled, phase 2/3 study to evaluate the efficacy and safety of masitinibin combination with gemcitabine versus gemcitabine alone in advanced/metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
  66. EPIK-B3, CBYL719H12301: - A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation
  67. A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non-Small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti PD (L)1 Therapy and Platinum-Based Chemotherapy- D533BC00001
  68. A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101)
  69. Amgen 20210081 - Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus Investigator's Choice Chemotherapy (FOLFOX or FOLFIRI) with or without Bevacizumab-awwb for Treatment-naïve Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation.
  70. Phase 3 randomized study of DS-1062A versus docetaxel in previously treated advanced or metastatic non-small-cell lung cancer without actionable genomic alterations (TROPION-LUNG01)

71. A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
72. A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Bladder Cancer in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)
73. A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors – INCB 86550-203
74. A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
75. CJDQ443B12301: A randomized, open label, phase III study evaluating JDQ443 or docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer – KontRASt-02
76. A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy – BGB-290-303
77. E0700 A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting (AMG 20220083)
78. ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) Unicancer-Peace 6 UC-GTG-2006
79. Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy - (VIKTORIA-1)
80. A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies
81. E0660 ASTEX - A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Moderate and Severe Hepatic Impairment
82. E0661 ASTEX - A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Severe Renal Impairment and Cancer Patients with Normal Renal Function
83. E0678 ASTEX -An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
84. E0757 JIMMY MEL SANDOZ Biosimilar - A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EU authorized Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab.
85. E0685 Beigene - A Phase 2, Open-label, Multi-Arm Study of Tieslizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer

86. E0594 - An open label trial of BI 765063 in combination with BI 754091 (ezabenzimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) (phase 1b)

#### **Books/Book chapters:**

1. **Principiile studiilor clinice în oncologie** – Coordonatori Alexandru C. Grigorescu, Rodica Anghel, *Editura Universitară „Carol Davila”, București, 2005.* – coautor capitol
2. **ESMO Course Gastrointestinal Malignancy** – Editors Alexandru C. Grigorescu, Rodica Anghel, Hans-Joachim Schmoll – *Editura Universitară „Carol Davila”, București, 2007.*- coautor capitol
3. **Oncologie generală – curs pentru studenți** – Coordonatori Rodica Anghel, Alexandru Blidaru - *Editura Universitară „Carol Davila”, București, 2007.*-autor un capitol și coautor 7 capitole
4. **Tratamentul medical al cancerului bronhopulmonar** – *Editura Medicală, București, 2008* – autor capitol
5. **Tratat de chirurgie** – volumul VIII Partea IB Chirurgie generală - sub coordonarea Prof. Dr. Irinel Popescu, *Editura Academiei Române, București 2008* – coautor capitol: Cancerul de sân ISBN 978-973-27-1579-6
6. **Actualități în diagnosticul și tratamentul sistemic al cancerului mamar** - *Editura Universitară „Carol Davila”, București, 2009,* autor
7. **Tratat de chirurgie** – volumul V, editia a doua – Obstetrică și Ginecologie – sub redacția Irinel Popescu și Constantin Ciuce, sub coordonarea Gheorghe Peltecu, *Editura Academiei Române, București 2014* – coautor capitol: Cancerul de col uterin
8. **Oncologie generală – Manual universitar,** coordonator Prof. Univ. Dr. Rodica Anghel, *Editura Universitară “Carol Davila” București 2019,* ISBN 978-606-011-045-3 - coautor 5 capitole

#### **Articles in extenso - ISI, PubMed, BDI, CNCSIS:**

1. [Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening](#) - Gales, LN; Păun MA; Anghel RM; Trifanescu, OG – *Cancers* 2024, vol 16, issue 6, DOI: 10.3390/cancers16061191
2. [Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy](#) - Toma, RV; Anca, Z; Trifanescu, OG; Gales, LN; Folea, AR; Stanca, L; Bîlteanu, L; Anghel, RM – *Medical Science Monitor* – Volume 29 DOI 10.12659/MSM.941754
3. **Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania** - Laurentiu Simion, Vlad Rotaru, Ciprian Cirimbei, **Laurentia Gales**, Daniela-Cristina Stefan, Sinziana Octavia Ionescu, Dan Cristian Luca, Horia Doran, Elena Chitoran – *Diagnostics* **2023**, 13(17), 2776; <https://doi.org/10.3390/diagnostics13172776>
4. [A Decade of Therapeutic Challenges in Synchronous Gynecological Cancers from the Bucharest Oncological Institute](#) - Laurentiu Simion, Elena Chitoran, Ciprian Cirimbei, Daniela-Cristina Stefan, Ariana Neicu, Bogdan Tanase, Sinziana Octavia Ionescu, Dan Cristian Luca, **Laurentia Gales**, Adelina Silvana Gheorghe, Dana Lucia

- Stanculeanu, Vlad Rotaru – *Diagnostics* 2023, 13(12), 2069; <https://doi.org/10.3390/diagnostics13122069>
5. **Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma** - Lucica Madalina Bolovan; Mihai Ceausu; Adina Elena Stanciu; Marieta Elena Panait; Antonela Busca; Camelia Mia Hotnog; Coralia Bleotu; **Laurentia Nicoleta Gales**; Mihai Teodor Georgescu; Virgiliu Mihail Prunoiu - *J. Pers. Med.* 2023, 13(6), 898; <https://doi.org/10.3390/jpm13060898>
  6. **Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis—A New Dimension of Molecular Imaging** - Mirela Gherghe; Alexandra Maria Lazar; Maria-Carla Sterea; Paula Monica Spiridon; Natalia Motas; **Laurentia Nicoleta Gales**; Daniel Coriu; Sorina Nicoleta Badelita; Mario-Demian Mutuleanu - *J. Cardiovasc. Dev. Dis.* 2023, 10(6), 242; <https://doi.org/10.3390/jcdd10060242>
  7. **The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma** - Alexandru-Rares Stoian; Gabriela Rahnea-Nita; Anda-Natalia Ciuhu; **Laurentia Gales**; Rodica-Maricela Anghel; Laura-Florentina Rebegea; Roxana-Andreea Rahnea-Nita; Liliana-Florina Andronache; Ioana Soare; Gabriela Stoleriu – *Diagnostics* 2023, 13(9), 1635; <https://doi.org/10.3390/diagnostics13091635> (autor contributie egala)
  8. **[Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis](#)** - Laurentiu Simion, Vlad Rotaru, Ciprian Cirimbei, Daniela-Cristina Stefan, Mirela Gherghe, Sinziana Ionescu, Bogdan Cosmin Tanase, Dan Cristian Luca, **Laurentia Nicoleta Gales** and Elena Chitoran - *Diagnostics* 2023, 13, 1040. <https://doi.org/10.3390/diagnostics13061040>
  9. **The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease** - **[Oana Gabriela Trifanescu, Raluca Alexandra Trifanescu, Radu Iulian Mitrica](#)**, Diana Maria Bran, Georgia Luiza Serbanescu, Laurentiu Valcauan, Serban Andrei Marinescu, **Laurentia Nicoleta Gales**, Bogdan Cosmin Tanase and Rodica Maricela Anghel – *Diagnostics* 2023, 13(5), 877; <https://doi.org/10.3390/diagnostics13050877>
  10. **Validation of a New Prognostic Score in Patients with Ovarian Adenocarcinoma** - Oana Gabriela Trifanescu, Radu Iulian Mitrica, **Laurentia Nicoleta Gales**, Serban Andrei Marinescu, Natalia Motas, Raluca Alexandra Trifanescu, Laura Rebegea, Mirela Gherghe, Dragos Eugen Georgescu, Georgia Luiza Serbanescu, Haj Hamoud Bashar, Serban Dragosloveanu, Daniel Alin Cristian and Rodica Maricela Anghel - *Medicina* 2023, 59, 229. <https://doi.org/10.3390/medicina59020229>
  11. **Burnout risk evaluation in medical oncology – radiotherapy personnel** – Laura Rebegea, Camelia Tarlungianu, Rodica Anghel, Dorel Firescu, Nadejda Corobcean, **Laurentia Gales** – *Archiv Euromedica* – January 2023 – DOI: 10.35630/2022/12/psy.ro.5
  12. **[Upstaging and Downstaging in Gliomas—Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System](#)** - Oana Gabriela Trifanescu, Raluca Alexandra Trifanescu, Radu Mitrică, Dan Mitrea, Ana Ciornei, Mihai Georgescu, Ioana Butnariu, **Laurenția Nicoleta Gales**, Luiza Șerbănescu, Rodica Maricela Anghel and Mihai-Andrei Păun – *Diagnostics* 2023, 13(2), 197; <https://doi.org/10.3390/diagnostics13020197>
  13. **[Risk of Myelopathy Following Second Local Treatment after Initial Irradiation of Spine Metastasis](#)** - **Laurentia Gales**, Diana Mitrea, Bogdan Chivu, Adrian Radu, Silvia Bocai, Remus Stoica, Andrei Dicianu, Radu Mitrica, Oana Trifanescu, Rodica Anghel and Luiza Serbanescu – *Diagnostics* 2023, 13(2), 175; <https://doi.org/10.3390/diagnostics13020175>

14. **[Oncologic Outcome after Pulmonary Metastasectomy as Part of Multidisciplinary Treatment in a Tertiary Oncological Center](#)** - Natalia Motas, Mihnea Dan Davidescu, Bogdan Cosmin Tanase, Ovidiu Rus, Alin Ionut Burlacu, Vlad Alexe, Veronica Manolache, Madalina Cristiana Mizea, Nicolae Gheorghiu, Oana Gabriela Trifanescu, **Laurentia Nicoleta Gales**, Teodor Horvat, Rodica Maricela Anghel - [Diagnostics](#) 2023, [Volume 13, Issue 1](#), 165, [10.3390/diagnostics13010165](#)
15. **[Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients](#)** - Oana Gabriela Trifanescu, **Laurentia Nicoleta Gales** (autor corespondent), Bogdan Cosmin Tanase, Serban Andrei Marinescu, Raluca Alexandra Trifanescu, Iuliana Maria Gruia, Mihai Andrei Paun, Laura Rebegea, Radu Mitrica, Luiza Serbanescu and Rodica Maricela Anghel - [Diagnostics](#) 2023, 13, 166. <https://doi.org/10.3390/diagnostics13010166>
16. **[Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?](#)** - Oana Gabriela Trifanescu, **Laurentia Nicoleta Gales** (autor corespondent), Mihai Andrei Paun, Natalia Motas, Serban Andrei Marinescu, Ion Virtosu, Raluca Alexandra Trifanescu, Mirela Gherghe, Liviu Bilteanu, Camelia Cristina Diaconu and Rodica Maricela Anghel - [Medicina](#) 2022, 59 (1), 50. <https://doi.org/10.3390/medicina59010050>
17. **Understanding COVID Vaccination and Its Implication in Cancer Patients' Imaging of Lymph Nodes by PET-CT - Gales LN, Brotea-Mosoiu S, Trifanescu OG, Lazar AM, Gherghe M** - [Diagnostics \(Basel\)](#). 2022 Sep 6;12(9):2163. doi: [10.3390/diagnostics12092163](#). PMID: 36140564; PMCID: PMC9497665.
18. **The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?** - Mirela Gherghe, Alexandra Maria Lazăr, Adina Elena Stanciu, Mario-Demian Mutuleanu, Maria-Carla Sterea, Cristina Petroiu and **Laurentia Nicoleta Gales** - [Cancers](#) 2022, 14, 2725. <https://doi.org/10.3390/cancers14112725>
19. **Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy - Gales, L.; Forsea, L.; Mitrea, D.; Stefanica, I.; Stanculescu, I.; Mitrica, R.; Georgescu, M.; Trifanescu, O.; Anghel, R.; Serbanescu, L.** – [Medicina](#). 2022 Sep 7;58(9):1239. <https://doi.org/10.3390/medicina58091239>
20. **Barriers and Facilitators of Romanian HPV (Human Papillomavirus) Vaccination** - Manolescu LSC, Zugravu C, Zaharia CN, Dumitrescu AI, Prasacu I, Radu MC, Letiția GD, Nita I, Cristache CM, **Gales LN**. - [Vaccines \(Basel\)](#). 2022 Oct 15;10(10):1722. doi: [10.3390/vaccines10101722](#). PMID: 36298587; PMCID: PMC9611461.
21. **Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO)** - Aapro, Matti; Caprariu, Zoe; Chilingirov, Petio; Chrapava, Marika; Curca, Razvan-Ovidiu; **Gales, Laurentia**; Grigorescu, Alexandru C.; Huszno, Joanna; Karlinova, Bara; Kellnerova, Renata; Malejcikova, Miroslava; Marinca, Mihai; Petru, Edgar; Pluzanski, Adam; Pokorna, Petra; Pribulova, Zuzana; Rubach, Maryna; Steger, Gunther G.; Tesarova, Petra; Valekova, Lubica; Yordanov, Nicolay; Walaszowska-Czyz, Anna - [European Journal of Cancer](#) on May 01, 2022 - [doi.org/10.1016/J.EJCA.2022.01.028](https://doi.org/10.1016/J.EJCA.2022.01.028)
22. **Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe An initiative of the Central European Cooperative Oncology Group (CECOG)** – Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, **Laurentia Nicoleta Gales**, Cvetka Grasic Kuhar, Urska Janzic, Zsusanna Kahan, Marina Mencinger, George Penthedourakis, Joseph Sgouros,

- Luka Simetic, Daniela Sirbu, Milan Vosmik, Anna Wrona, Christoph Zielinski - [Wiener Klinische Wochenschrift on March 21, 2022, 134, p697-704](#) - [doi.org/ 10.1007/S00508-022-02016-Z](#)
23. **Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania** - Trifanescu, Oana Gabriela; **Gales, Laurentia**; Bacinschi, Xenia; Serbanescu, Luiza; Georgescu, Mihai; Sandu, Alexandra; Michire, Alexandru; Anghel, Rodica - [In Vivo on March 02, 2022- doi.org/ 10.21873/INVIVO.12783](#), **IF – 2.155**
  24. **Clinical, histological and therapeutical aspects in the management of uterine and extrauterine stromal sarcomas: Case reports** - Rebegea, Laura Florentina; Firescu, Dorel; Anghel, Rodica Marcela; **Gales, Laurentia**; Ilie, Ana Maria; Dumitru, Mihaela Emilia; Craescu, Mihaela; Niculet, Elena; Tatu, Alin Laurentiu; Cretu, Mariana Stuparu; Lungu, Mihaela; Neagu, Anca Iulia - [Experimental and Therapeutic Medicine on December 01, 2021](#) - [doi.org/10.3892/ETM.2021.10891](#), **IF – 2.447**
  25. **Modulation of Immune System - Strategy in the Treatment of Breast Cancer** - Badiu, Dumitru Cristinel; Zgura, Anca; **Gales, Laurentia**; Iliescu, Laura; Anghel, Rodica; Haineala, Bogdan - [In Vivo in September, 2021, 35, 2889-2894](#) - [doi.org/10.21873/INVIVO.12578](#), **IF – 2.155**
  26. **Aspects Regarding the Influence of Obesity on the Molecular Characteristics of Breast Tumors** - Pantelimon I, **Gales LN**, Anghel RM, Gruia MI, Nita I, Matei CV, Bodea D, Stancu AM, Pirvu E, Radu MC, Dumitrescu AI, Manolescu LSC - *Cureus*. 2022 Jul 17;14(7):e26952. doi: 10.7759/cureus.26952. PMID: 35989732; PMCID: PMC9381069.
  27. **A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania** - Bacinschi X, Popescu GC, Zgura A, **Gales L**, Rodica A, Mercan A, Serban D, Haineala B, Toma L, Iliescu L - *Med Sci Monit*. 2022 Jul 5;28:e936706. doi: 10.12659/MSM.936706. PMID: 35787600; PMCID: PMC9270854.
  28. **Analysis of Oxidative Stress in Patients with Breast Cancer and Obesity** - Pantelimon, Iuliana; **Gales, Laurentia Nicoleta**; Zgura, Anca; Serbanescu, Georgia Luiza; Georgescu, Dragos Eugen; Nita, Irina; Manolescu, Loredana Sabina Cornelia; Stancu, Andra Maria; Gruia, Maria Iuliana; Anghel, Rodica Maricela; Badiu, Dumitru Cristinel - [Annals of Medical and Health Sciences Research](#) in June, 2021 Volume 11, Issue 6, Page 1578-1585 - [publons.com/p/50701951/](#)
  29. **Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy** - Xenia Elena, Bacinschi; **Nicoleta Gales, Laurentia**; Florina Zgura, Anca; Iliescu, Laura; Maricela Anghel, Rodica; Haineala, Bogdan - [Journal of Oncology on May 04, 2021, Nr 1](#) - [doi.org/ 10.1155/2021/6698969](#), **IF – 4.375**
  30. **Long-term oncological outcome in patients with cervical cancer after 3 trimodality treatment (radiotherapy, platinum-based chemotherapy, and robotic surgery)** - Trifanescu OG, **Gales LN**, Serbanescu GL, Zgura AF, Iliescu L, Mehedintu C, Anghel RM. *Medicine* 2021;100:13(e25271)
  31. **When Should We Expect Curative Results of Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients?** - Mihai-Teodor Georgescu, Traian Patrascu, Luiza Georgia Serbanescu, Rodica Maricela Anghel, **Laurentia Nicoleta Gales** (autor correspondent), Florin Teodor Georgescu, Radu Iulian Mitrica, Dragos Eugen Georgescu - *Chirurgia* (Bucharest, Romania: 1990) 116(1):16-23 - DOI: [10.21614/chirurgia.116.1.16](#) January 2021

32. [Dynamic evaluation of the immune response of Cancer Patients Treated with Immunotherapy](#) - Xenia Elena Bacinschi, **Laurentia Nicoleta Gales**, Anca Florina Zgura, Oana Gabriela Trifanescu, Laura Iliescu and Rodica Maricela Anghel - Volume10-Issue5, Pages: 460-467, Oct 2020
33. [An exceptional response to immunotherapy with chemotherapy in metastatic lung cancer](#) – Xenia Bacinschi, **Laurentia Gales**, Zgura Anca, Rodica Anghel - June 2020 - Romanian Journal of Medical Practice 15(2):245-248 DOI: [10.37897/RJMP.2020.2.21](#)
34. [Impact of adding a platinum agent \(carboplatin\) to paclitaxel vs. Paclitaxel alone in mbc. A romanian centre experience](#) – Silvia Brotea-Mosoiu, **Laurentia Gales**, Denisa Ciochir, Valentina Chiriac - November 2019 The Breast - DOI: [10.1016 / S0960-9776 \(19\) 30703-9, 2021 Impact Factor 4.254](#)
35. **Immune Effects of Transtuzumab in HER2 Positive Breast Cancer** - Anca Zgura, **Laurentia Gales**, Bogdan Haineala, Elvira Bratila, Claudia Mehedintu, Ramona Ileana Barac, Costin Berceanu, Cristina Veronica Andreescu, Lacramioara Aurelia Brinduse, Alec Ionescu, Rodica Anghel - Revista de Chimie, 2019, vol 70, nr 8, p2791-2794, **IF 1.76**
36. **Correlations Between Known Prognostic Markers and Tumor - infiltrating Lymphocytes in Breast Cancer** - Anca Zgura, **Laurentia Gales** (autor cu contributie egala), Bogdan Haineala, Elvira Bratila, Claudia Mehedintu, Cristina Veronica Andreescu, Costin Berceanu, Aida Petca, Ramona Ileana Barac, Alec Ionescu, Rodica Anghel - Revista de Chimie, 2019, vol 70, nr 7, p2362-2366, **IF 1.76**
37. **Malondialdehyde as a prognostic marker in patients with ovarian adenocarcinoma**, Oana Trifanescu, Maria Iuliana Gruia, **Laurentia Gales**, Raluca Trifanescu, Alina Mihaela Pascu, Vladimir Poroch, Sebastian Toma, Catalina Poiana, Rodica Anghel. Revista de Chimie 2019; 70(7):2561-2565, Journal ISSN: 0034-7752, <http://www.revistadechimie.ro/pdf/53%20TRIFANESCU%207%2019.pdf>, Revistă cotată ISI Clarivate Analytiscs/ Thomson Reuters. Factor de impact 1,605
38. **“Giant phyllodes tumor of the breast“** - Anca Zgură, **Laurentia Gales**, Elvira Bratila, Rodica Anghel - GINECOLOGIA Anul VII Nr. 23 (1/2019) DOI:10.26416/Gine.23.1.2019.2221
39. **“Types of response and pseudoprogession to immunotherapy in lung cancer“**, Anca Zgură, **Laurenția Gales**, Bogdan Haineala, Elvira Bratila and Rodica Anghel, PROC.ROM.ACAD, Series B 2019, 21(1), p. 47–50
40. **“Variation of the T lymphocytes according to treatment in breast cancer“** - Anca Zgură, **Laurentia Gales** (autor cu contributie egala), Elvira Bratila, Claudia Mehedintu, Bogdan Haineala, Ramona Ileana Barac, Amarin Remus Popa, Camelia Buhas, Costin Berceanu, Cristina Veronica Andreescu, Rodica Anghel, REV.CHIM.( Bucharest), 70, No. 5, p1649-1654, 2019
41. **Clinical Prognostic Factors in pre-and Post-Menopausal Women with Ovarian Carcinoma**, Trifanescu OG, **Gales LN**, Trifanescu RA, Anghel RM, Acta Endo (Buchar) 2018 Jul-Sep;14(3):353-359. DOI: 10.4183/aeb.2018.353. <https://acta-endo.ro/2018/numarul3/fulltext/35359%20O.G.%20Trifanescu.pdf>. ISSN 1841-0987, eISSN 1843-066X. Revistă cotată ISI Clarivate Analytiscs/ Thomson Reuters. Factor de impact 0,411.
42. **Tumor is an Oxidative Stress Factor in Ovarian Cancer Patients**. Trifanescu O, Gruia MI, **Gales L**, Trifanescu R, Anghel R. Chirurgia (Bucur). 2018 Sept-Oct;113(5):687-694, Online ISSN: 1842 – 368X, ISSN: 1221-9118. DOI:10.21614/chirurgia.113.5.687. Revistă cotată ISI Thomson Reuters,
43. **Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment**. Anghel R,

- Constantinoiu S, Bacinschi X, **Gales L**, Toma RV, Trifanescu O. Chirurgia (Bucur). 2018 Jan-Feb;113(1):116-122, Online ISSN: 1842 – 368X, ISSN: 1221-9118. Revistă cotată ISI Thomson Reuters,
44. **“Relația dintre infiltratul limfocitar tumoral și progresia în cancerul de sân triplu negativ”**, - Anca Zgură, **Laurenția Gales**, Mihai Mitran, Elvira Brătilă, Rodica Anghel, GINECOLOGIA Anul VI • Nr. 21 (3/2018)
  45. **Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer** – A. Zgura, **L. Gales**, E. Bratila, R. Anghel – Maedica – A Journal of Clinical Medicine 2018; vol.13 nr. 4: 317-320
  46. **“The role of tumor-infiltrating lymphocytes in triple negative breast cancer-case study”**, - Assist. Prof. Anca Zgură, MD, Simona Carniciu , MD, **Assoc. Prof. Laurentia Gales**, MD, PhD, Prof. Rodica Anghel, MD, PhD, PRACTICA MEDICALĂ – VOL. 13, NR. 3(59), AN 2018
  47. **“Colorectal cancer during pregnancy”** - Anca Zgură, **Laurentia Gales**, Elvira Bratila, Rodica Anghel, , GINECOLOGIA, Anul VI • Nr. 22 (4/2018)
  48. **”Comparison of tumor infiltrating lymphocytes between primary and metastatic tumors in Her2+ and Her2- breast cancer patients”** - Claudia Mehedintu, Elvira Bratila, Costin Berceanu, Monica Mihaela cirstoiu, Ramona Ileana Barac, Cristina Veronica Andreescu, Dumitru Cristinel Badiu, **Laurenția Gales** (autor cu contributie egala), Anca Zgură, Adrian Gheorghe Bumbu, REV.CHIM.(Bucharest),69,No.11, p3133-3137, 2018
  49. **Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma – the Romanian Patient Access Program** Dana- Lucia Stanculeanu, Dan Corneliu Jinga, Tudor Ciuleanu, Serban Negru, Ciprian Aldea, **Laurentia Gales**, Florin Bacanu, Cristina Oprean, Mihai Manolache, Daniela Zob, Stefan Curescu - JBUON 2017; 22(5): 1287-1295 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com E-mail: [editorial\\_office@jbuon.com](mailto:editorial_office@jbuon.com) **IF 1,766**
  50. **Current status of the first and second line therapy for Helicobacter pylori infection in symptomatic children: A single center study** - Hurduc, V.; Bordei, L.; **Gales, L.**; Plesca, D. - Published: 2017 in Helicobacter DOI: 10.26226/MORRESIER.59A6B345D462B80290B548BE
  51. **Helicobacter pylori infection and specific immunoglobulin E antibodies to food allergens in symptomatic children admitted in a digestive endoscopy unit** - Hurduc, V.; Bordei, L.; **Gales, L.**; Plesca, D. - Published: 2017 in Helicobacter DOI: 10.26226/MORRESIER.59A6B345D462B80290B548BE
  52. **A study regarding boron metabolism at experimental animals in order to achieve neutron irradiation in boron capture** - **Laurenția N. Gales**, Rodica Anghel, Marian Iuliana Gruia, Ion Gruia, Adrian Birloiu, Alexandra Raluca Miron – Revista de Chimie – vol 67, nr 6/2016 (ISI)
  53. **Applicability of ferromagnetic nanoparticles in surface water treatment with biological loads** – D.D. Slave (Clej), **Laurenția N. Gales**, Szidonia Katalin Tanczos, hussam Nadum Abd Alraheem Al-Ani, V.I. Panait, A.C. Nechifor - Revista de Chimie – acceptat spre publicare vol 67, nr 6/2016 (ISI)
  54. **Outcome of urinary bladder cancer after combined therapies** - Rodica M Anghel, **Laurenția N. Gales**, Oana G. Trifănescu – Journal of Medicine and Life – acceptat spre publicare 2016 (CNCSIS B+)
  55. **Terapia cu neutroni în captură de Bor: Substanțe folosite pentru administrarea borului** - **Dr. Laurenția N. Gales**, Prof. Dr. Rodica M Anghel - Therapeutics pharmacology and clinical toxicology, ian 2016 (CNCSIS B+)

56. **In vivo study of BPA (boron10-phenilalanine) use in Boron Neutron Capture radiotherapy as an alternative for Hepatic cancer treatment -** **Laurentia Gales**, Rodica Anghel, Maria Iuliana Gruia, Valeria Lungu, Valentina Negoita, Ion Gruia – Rom. Journ. Phys., Vol. 60, Nos.3-4, p521-527, Bucharest, 2015 (ISI)
57. **Factori de prognostic in evolutia carcinomului ovarian cu debut in pre si postmenopauza** O Trifanescu, **L Gales**, R Trifanescu, R Anghel, Congresul National de Endocrinologie, Iasi 24 iunie 2015 Lucrare publicata In Acta Endocrinologica Vol XI Suplement Nr1 June 2015, ISSN 1841-0987, Revistă cotată ISI Thomson Reuters, CNCSIS A, Impact factor= 0,411
58. **Experiența clinică pe plan mondial cu terapie cu neutroni în captură de Bor (BNCT) - Dr. Laurenția N. Gales**, Therapeutics pharmacology and clinical toxicology, dec 2015 (CNCSIS B+)
59. **Results obtained from the association of boron neutron capture therapy with Bevacizumab -** **Laurentia Gales**, Prof. Dr. Rodica Anghel, Maria Iuliana Gruia, Valentina Negoita Monica Vasilescu, Marieta Panait, D. Barbos, I.Gruia - Therapeutics pharmacology and clinical toxicology, Vol 18, Nr 4, p 160-163, dec 2014 (CNCSIS B+)
60. **Identification of Some Radio-Biochemical Effects Consecutive Boron Neutron Capture Therapy at Experimental Hepatoma Cells -** **Laurentia Gales**, Maria Iuliana Gruia, Valentina Negoita Monica Vasilescu, Marieta Panait, D. Barbos, I.Gruia, Rodica Anghel – Therapeutics pharmacology and clinical toxicology, Vol 18, Nr 3, p104-108, sep 2014 (CNCSIS B+)
61. **Targeted Therapy in Combination with Radiation Therapy in Head and Neck Cancer -** R. Anghel, **L. Gales**, C. Nitipir, Journal of Medicine and Life, Vol VI Special Issue 1, 2013, ISSN 1844 – 122x (CNCSIS B+)
62. **Tendințe actuale in managementul cancerului mamar ECCO12 – Copenhaga –** Dana Stanculeanu, **Laurenția Minea**, Alexandrina Crîngeanu – Revista Română de Oncologie – vol 40, nr 1, 2003
63. **Diphereline – o alta posibilitate de tratament a cancerului de prostată –** Dana Stănculeanu, Ion Bălănescu, Rodica Anghel, **Laurenția Minea**, Alexandrina Crîngeanu - Revista Română de Oncologie – vol 39, nr 1-2, 2002
64. **Tratamentul tumorilor ovariene – L. Minea**, Revista Română de Oncologie – vol 37, nr 1-2, 2000 Tratamentul cancerelor ovariene (protocol terapeutic). D.Stanculeanu, N. Gutulescu, R. Anghel, I. Balanescu, N. Minea. Revista romana de oncologie, vol.37(1), 24-33, 2000

**DATE:** \_\_14 JUN 2025\_\_  
**DD-MMM-YYYY**

**PRINTED NAME: LAURENȚIA  
NICOLETA GALEȘ**